An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO) - NCT00726661-60099 (Clinical Trial 234491)
Permalink: http://www.ClinicalConnection.com/exp/ExpandedPatientViewStudy234491.aspx
|
** Please review additional "Nearby Studies" on right ----->
|
|
 |
 |
|
| City: |
|
Zion |
|
State:
|
|
IL |
| Zip Code: |
|
60099 |
| Conditions: |
|
Breast Cancer |
| Purpose: |
|
This is a multicenter, prospective OCS designed to follow patients with locally recurrent or
metastatic breast cancer in the United States. Two cohorts will be included:
- Patients with HER2-normal disease receiving their first cytotoxic chemotherapy and/or
targeted therapy (1500 patients)
- Patients with HR-positive tumors receiving their first HT for advanced disease (500
patients) Patients who started their first systemic treatment for advanced breast
cancer within 1 month prior to enrollment into this OCS will be eligible. A total of
approximately 2000 patients will be enrolled. In order to assure that treatment
patterns over time are represented in the study, the number of sites activated will be
determined by projections to achieve complete enrollment over approximately 18-24
months.
|
| Study summary: |
|
|
| Criteria: |
|
Inclusion Criteria:
- Signed Informed Consent Form
- Locally recurrent or metastatic breast cancer
- Receipt of first systemic cytotoxic chemotherapy and/or targeted therapy among those
with HER2-normal disease or first hormone therapy among those with HR-positive
disease for the treatment of locally recurrent or metastatic disease, no greater than
1 month prior to enrollment
Exclusion Criteria
- Any medical condition, including mental illness or substance abuse, deemed by the
investigator to be likely to interfere with a patient's ability to provide informed
consent or comply with the treatment
- Concurrent participation in a blinded clinical trial |
|
|
|
| Study is available at: |
|
Midwestern Regional Med Center
Zion, IL 60099
United States
Primary Contact:
Joy Jardinico
Email: joy.jardinico@mrmc-ctca.com
Phone: 847-731-4143
Secondary Contact:
Trial Information Support Line
Phone: 866-850-9521 |
|
|
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
|
| Trials Alerts: |
|
If you would like to be
notified of new clinical trials as they become available please
register for a free account.
|
|
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
March 16, 2010 |
Modifications to
this listing: |
|
Only selected fields are shown, please use the link
above to view all information about this clinical trial. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Clinical trials are medical research studies designed to test the safety and/or
effectiveness of new drugs, devices, or treatments in humans. These studies are
conducted worldwide for a range of conditions and illnesses. Learn more about
clinical research and participating in a study at
About Clinical Trials.
|
|
|
|
|